Literature DB >> 12076321

Mast cell/T cell interactions in oral lichen planus.

Z Z Zhao1, N W Savage, P B Sugerman, L J Walsh.   

Abstract

Lichen planus is a disorder characterized by lesions of the skin and oral mucous membranes. Although many patients have involvement of both skin and oral mucosa at some stage during the progress of the disease, a larger group has oral involvement alone. It has been reported that oral lichen planus (OLP) affects one to two percent of the general population and has the potential for malignant transformation in some cases (1, 2). Like many chronic inflammatory skin diseases, it often persists for many years. Numerous disorders may be associated with OLP such as graft-vs.-host disease and Hepatitis C virus infection (3), however, it is unclear how such diverse influences elicit the disease and indeed whether they are identical to idiopathic OLP. Available evidence supports the view that OLP is a cell-mediated immunological response to an induced antigenic change in the mucosa (4-6). Studies of the immunopathogenesis of OLP aim to provide specific novel treatments as well as contributing to our understanding of other cell-mediated inflammatory diseases. In this paper, the interactions between mast cells and T cells are explored from the standpoint of immune regulation. From these data, a unifying hypothesis for the immunopathogenesis of OLP is then developed and presented.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076321     DOI: 10.1034/j.1600-0714.2002.310401.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  18 in total

1.  Mechanisms of viral infections associated with HIV: workshop 2B.

Authors:  S M Tugizov; J Y Webster-Cyriaque; S Syrianen; A Chattopadyay; H Sroussi; L Zhang; A Kaushal
Journal:  Adv Dent Res       Date:  2011-04

2.  Skew in T cell receptor usage with polyclonal expansion in lesions of oral lichen planus without hepatitis C virus infection.

Authors:  A Gotoh; Y Hamada; N Shiobara; K Kumagai; K Seto; T Horikawa; R Suzuki
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

3.  Oral lichen planus treated with 13-cis-retinoic acid (isotretinoin): effects on the apoptotic process.

Authors:  Adriano Piattelli; Francesco Carinci; Giovanna Iezzi; Vittoria Perrotti; Gaia Goteri; Massimiliano Fioroni; Corrado Rubini
Journal:  Clin Oral Investig       Date:  2007-05-05       Impact factor: 3.573

4.  Hydroxychloroquine decreases the upregulated frequencies of Tregs in patients with oral lichen planus.

Authors:  Yanan Zhu; Jingjing Li; Yang Bai; Xiang Wang; Ning Duan; Hongliu Jiang; Tingting Wang; Wenmei Wang
Journal:  Clin Oral Investig       Date:  2014-01-14       Impact factor: 3.573

5.  Serum autoantibodies to desmogleins 1 and 3 in patients with oral lichen planus.

Authors:  Josip Lukac; Suzana Brozović; Vanja Vucicević-Boras; Marinka Mravak-Stipetić; Branko Malenica; Zvonko Kusić
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

6.  The comparison of efficacy of adcortyl ointment and topical tacrolimus in treatment of erosive oral lichen planus.

Authors:  Arash Azizi; Shirin Lawaf
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2007-12-20

7.  Role of mast cells in pathogenesis of oral lichen planus.

Authors:  Rachna Sharma; Keya Sircar; Sanjeet Singh; Varun Rastogi
Journal:  J Oral Maxillofac Pathol       Date:  2011-09

Review 8.  Diagnostic Criteria of Oral Lichen Planus: A Narrative Review.

Authors:  Doina Iulia Rotaru; Diana Sofineti; Sorana D Bolboacă; Adriana E Bulboacă
Journal:  Acta Clin Croat       Date:  2020-09       Impact factor: 0.780

9.  Degranulated mast cells and TNF-α in oral lichen planus and oral lichenoid reactions diseases.

Authors:  Parichehr Ghalayani; Gholamreza Jahanshahi; Zahra Saberi
Journal:  Adv Biomed Res       Date:  2012-08-28

10.  Alterated integrin expression in lichen planopilaris.

Authors:  Roberto d'Ovidio; Concetta Sgarra; Anna Conserva; Umberto Filippo Angelotti; Roberta Erriquez; Caterina Foti
Journal:  Head Face Med       Date:  2007-02-08       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.